Endocrine oncology (Bristol, England)

Keyphrases

Publications

volume 3, number 1, 2023

Vineeth K Sukrithan, Prachi Jain, Manisha H Shah, Bhavana Konda
Kinase inhibitors in thyroid cancers. Endocrine oncology (Bristol, England) 3 (1) (2023)
Trinidad Raices, María Luisa Varela, Adriana María Belén Abiuso, Elba N Pereyra, Carolina Mondillo, Omar P Pignataro, María Fernanda Riera
Curcumin effects on Leydig cell functions and potential therapeutic uses. Endocrine oncology (Bristol, England) 3 (1) (2023)
Gido Snaterse, Johannes Hofland, Bruno Lapauw
The role of 11-oxygenated androgens in prostate cancer. Endocrine oncology (Bristol, England) 3 (1) (2023)
Nele F Lenders, Peter E Earls, Warrick J Inder, Ann I McCormack
The evolution in pituitary tumour classification: a clinical perspective. Endocrine oncology (Bristol, England) 3 (1) (2023)
Lucinda M Gruber, Steven N Hart, Louis James Maher Iii
Succinate dehydrogenase variants in paraganglioma: why are B subunit variants 'bad'? Endocrine oncology (Bristol, England) 3 (1) (2023)
Joel George, John K Ramage, Benjamin White, Rajaventhan Srirajaskanthan
The role of serotonin inhibition within the treatment of carcinoid syndrome. Endocrine oncology (Bristol, England) 3 (1) (2023)
Stéphanie Larose, Dany Rioux, Roula Albadine, André Lacroix
Ectopic ACTH Cushing's syndrome caused by a large-cell neuroendocrine lung carcinoma responding to desmopressin. Endocrine oncology (Bristol, England) 3 (1) (2023)
Sofia Maria Lider Burciulescu, Caren Randon, Frederic Duprez, Wouter Huvenne, David Creytens, Kathleen B M Claes, Robin de Putter, Guy T'Sjoen, Corin Badiu, Bruno Lapauw
Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma. Endocrine oncology (Bristol, England) 3 (1) (2023)
Macarena Contreras Angulo, Belén García Izquierdo, Laura Armengod Grao, Nuria Palacios García
Thrombotic microangiopathy associated with lenvatinib therapy. Endocrine oncology (Bristol, England) 3 (1) (2023)
Katherine A English, Rajesh V Thakker, Kate E Lines
The role of DNA methylation in human pancreatic neuroendocrine tumours. Endocrine oncology (Bristol, England) 3 (1) (2023)
Benjamin J Worrall, Alexander James Papachristos, Ahmad Aniss, Anthony Glover, Stan B Sidhu, Roderick John Clifton-Bligh, Diana Learoyd, Venessa H M Tsang, Matti Gild, Bruce G Robinson, Mark S Sywak
Lobectomy and completion thyroidectomy rates increase after the 2015 American Thyroid Association Differentiated Thyroid Cancer Guidelines update. Endocrine oncology (Bristol, England) 3 (1) (2023)
José V Lima, Nilza M Scalissi, Kelly C de Oliveira, Susan C Lindsey, Caroline Olivati, Elisa Napolitano Ferreira, Claudio E Kater
Germline genetic variants in pheochromocytoma/paraganglioma: single-center experience. Endocrine oncology (Bristol, England) 3 (1) (2023)
Molly Endicott, Chrissie Thirlwell, Amy P Webster
Exploring genetic loci of type 2 diabetes and cancer: a review. Endocrine oncology (Bristol, England) 3 (1) (2023)
Justo P. Castaño
Endocrine Oncology : the home for translational research in cancer and hormones. Endocrine oncology (Bristol, England) 3 (1) (2023)
Prabesh Khatiwada, Ujjwal Rimal, Mamata Malla, Zhengyang Han, Lirim Shemshedini
Peptides disrupting TM4SF3 interaction with AR or AR-V7 block prostate cancer cell proliferation. Endocrine oncology (Bristol, England) 3 (1) (2023)
Yuko Matsuo, Kenji Ashida, Ayako Nagayama, Kanoko Moritaka, Mizuki Gobaru, Junichi Yasuda, Naoyuki Ogasawara, Hirofumi Kurose, Katsuaki Chikui, Shimpei Iwata, Yukihiro Inoguchi, Nao Hasuzawa, Seiichi Motomura, Tsukasa Igawa, Masatoshi Nomura
Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma. Endocrine oncology (Bristol, England) 3 (1) (2023)

volume 3, number 1, 2022

Annabelle G Hayes, Masoumeh G Shirazi, Anand Thiyagarajah, David J Torpy, Sunita M C De Sousa
Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma. Endocrine oncology (Bristol, England) 3 (1) (2022)

volume 2, number 1, 2022

Anna Stroud, Pearl Dhaliwal, Richard J Harvey, Raquel Alvarado, Benjamin P Jonker, Mark J Winder, Jessica W Grayson, Ann I McCormack
Low but not undetectable early postoperative nadir serum cortisol predicts sustained remission in Cushing's disease. Endocrine oncology (Bristol, England) 2 (1) (2022)
Sylvia L Asa, Shereen Ezzat
Pituitary carcinoma: reclassification and implications in the NET schema. Endocrine oncology (Bristol, England) 2 (1) (2022)
Erina Iwabuchi, Yasuhiro Miki, Takashi Suzuki, Hironobu Sasano
Visualization of the protein-protein interactions of hormone receptors in hormone-dependent cancer research. Endocrine oncology (Bristol, England) 2 (1) (2022)
Donatella Treppiedi, Rosa Catalano, Federica Mangili, Giovanna Mantovani, Erika Peverelli
Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer. Endocrine oncology (Bristol, England) 2 (1) (2022)
Erika Peverelli, Donatella Treppiedi, Giovanna Mantovani
Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations. Endocrine oncology (Bristol, England) 2 (1) (2022)
Nadia Gagnon, Sophie Bernard, Martine Paquette, Catherine Alguire, André Lacroix, Pierre-Olivier Hétu, Harold J Olney, Isabelle Bourdeau
Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma. Endocrine oncology (Bristol, England) 2 (1) (2022)
Ana Rita Elvas, Andreia Martins Fernandes, Sara Reis, Joana Couto, Raquel G Martins, Jacinta Santos, Teresa Martins, Bernardo Marques, Joana Guimarães, Fernando J C Rodrigues
Transient remission of hyperparathyroidism after fine-needle aspiration biopsy. Endocrine oncology (Bristol, England) 2 (1) (2022)
Damien A Leach, Rayzel C Fernandes, Charlotte Lynne Bevan
Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer. Endocrine oncology (Bristol, England) 2 (1) (2022)
Sandra Pekic, Marko Stojanovic, Vera Popovic
Pituitary tumors and the risk of other malignancies: is the relationship coincidental or causal? Endocrine oncology (Bristol, England) 2 (1) (2022)
Ruaa Al-Ward, Celeste Zsembery, Mouhammed Amir Habra
Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options. Endocrine oncology (Bristol, England) 2 (1) (2022)
Darran Mc Donald, Rachel Katherine Crowley
Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic-pituitary-adrenal axis suppression. Endocrine oncology (Bristol, England) 2 (1) (2022)
Kiyoshi Takagi, Mio Yamaguchi, Minoru Miyashita, Hironobu Sasano, Takashi Suzuki
Diverse role of androgen action in human breast cancer. Endocrine oncology (Bristol, England) 2 (1) (2022)
Poh Shean Wong, Subashini Rajoo, Hairuddin Achmad Sankala, Mohamed Badrulnizam Long Bidin
Unusual presentation of lung carcinoma with pituitary metastasis: a challenging diagnosis and sodium management dilemmas. Endocrine oncology (Bristol, England) 2 (1) (2022)
Sean T McSweeney, Hannah E Bergom, Anna Prizment, Susan Halabi, Nima Sharifi, Charles Ryan, Justin H Hwang
Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer. Endocrine oncology (Bristol, England) 2 (1) (2022)
Darran Mc Donald, M Sherlock, C J Thompson
Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer. Endocrine oncology (Bristol, England) 2 (1) (2022)
Christie G Turin, Molly M Crenshaw, Lauren Fishbein
Pheochromocytoma and paraganglioma: germline genetics and hereditary syndromes. Endocrine oncology (Bristol, England) 2 (1) (2022)
Alexander Kreze, Matěj Homer, Tereza Barešová, Kristina Klemperová
Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab. Endocrine oncology (Bristol, England) 2 (1) (2022)
Krishna Vikneson, Tariq Haniff, May Thwin, Ahmad Aniss, Alex Papachristos, Mark Sywak, Anthony Glover
Tumour volume is a predictor of lymphovascular invasion in differentiated small thyroid cancer. Endocrine oncology (Bristol, England) 2 (1) (2022)
Sara Coelho, Cláudia Costa, Ana Paula Santos, Pedro Souteiro, Joana Oliveira, Júlio Oliveira, Isabel Azevedo, Isabel Torres, Maria José Bento
Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive center. Endocrine oncology (Bristol, England) 2 (1) (2022)
Syed Ehsanullah, Nikolaos A Trikalinos
Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine. Endocrine oncology (Bristol, England) 2 (1) (2022)
Sunita M C De Sousa
Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management? Endocrine oncology (Bristol, England) 2 (1) (2022)
Marcus Vetter, Karin M Rothgiesser, Qiyu Li, Hanne Hawle, Wolfgang Schönfeld, Karin Ribi, Salome Riniker, Roger von Moos, Andreas Trojan, Elena Kralidis, Mathias Fehr, Andreas Müller, Beat Thürlimann, null null
SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients. Endocrine oncology (Bristol, England) 2 (1) (2022)
Nathan J Graham, Joshua D Smith, Tobias Else, Gregory J Basura
Paragangliomas of the head and neck: a contemporary review. Endocrine oncology (Bristol, England) 2 (1) (2022)
Yixi Bi, Safwaan Adam, Viktoria Chatzimavridou, Paul Lorigan, Yinglai Huang
Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic-pituitary-adrenal axis abnormalities: a clinical case. Endocrine oncology (Bristol, England) 2 (1) (2022)

volume 1, number 1, 2021

Edward P Gelmann
The expanding role of hormones in cancer. Endocrine oncology (Bristol, England) 1 (1) (2021)
Patrick W Owens, Terri Patricia McVeigh, Nicola Miller, Carole Guerin, Frederic Sebag, Denis Quill, Marcia Bell, Michael J Kerin, Aoife J Lowery
FOXE1 polymorphism rs965513 predisposes to thyroid cancer in a European cohort. Endocrine oncology (Bristol, England) 1 (1) (2021)
Eleanor Fewings, Serena Khoo Sert Kim, Alexey Larionov, Alison Marker, Olivier Giger, Ashley Shaw, Graeme R Clark, Vasilis Kosmoliaptsis, Benjamin G Challis, Marc Tischkowitz, Ruth T Casey
Investigating the clinical, pathological and molecular profile of oncocytic adrenocortical neoplasms: a case series and literature review. Endocrine oncology (Bristol, England) 1 (1) (2021)
Laura Gerard, David Barthelemy, Arnaud Gauthier, Valerie Hervieu, Jonathan Lopez, Benjamin Gibert, Helene Lasolle, Laurence Chardon, Jessica Garcia, Gérald Raverot, Léa Payen, Thomas Walter
cfDNA in pancreatic neuroendocrine carcinoma management with Cushing's syndrome. Endocrine oncology (Bristol, England) 1 (1) (2021)
Nada Younes, Isabelle Bourdeau, Harold Olney, Paul Perrotte, Odile Prosmanne, Mathieu Latour, David Roberge, André Lacroix
Adrenocortical cancer recurrence following initial transcutaneous biopsy: a rare demonstration of needle tract seeding. Endocrine oncology (Bristol, England) 1 (1) (2021)
K E Lines, M Stevenson, R Mihai, I V Grigorieva, O A Shariq, K U Gaynor, J Jeyabalan, M Javid, R V Thakker
Hypoxia stimulates angiogenesis and a metabolic switch in human parathyroid adenoma cells. Endocrine oncology (Bristol, England) 1 (1) (2021)
T U Kars, M Kulaksızoğlu, I Kılınç
Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study. Endocrine oncology (Bristol, England) 1 (1) (2021)
Sarah Craus, Mark Gruppetta
Epidemiology of craniopharyngiomas: a population-based study in Malta. Endocrine oncology (Bristol, England) 1 (1) (2021)